Category Archives: People

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update on secondary endpoints, with quantitative autofluorescence showing a marked divergence between treatment groups New Drug Application to the U.S. Food and Drug Administration for tinlarebant […]

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team 

WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug […]

Burntide Gummies Launch 2026 | Advanced Weight Loss Formula Highlights Ingredients, Supplement Facts Available in USA, UK, CA, By BurnTide.

BurnTide Announcing updated ingredient information, supplement facts, usage guidance, and customer support details, giving consumers a complete overview before choosing the Weight Loss Gummies Formula. New York City, July 19, 2026 (GLOBE NEWSWIRE) — In 2026, we are proud to announce the launch of Burntide, a truly effective natural gummy thoughtfully designed to support your […]

ColestZen Official Launch 2026 | Cholesterol Support Capsules Available in USA, UK, CA & AU Market By Colestzen Supplement.

ColestZen Official Store announces ColestZen Supplement, formulated with carefully selected ingredients to support healthy cholesterol, support healthy blood sugar levels already within the normal range, and promote everyday wellness as part of a balanced lifestyle. New York City, July 18, 2026 (GLOBE NEWSWIRE) —     In 2026, we announced the launch of ColestZen to […]

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), […]

Vireo Growth Inc. Completes Acquisition of Pennsylvania Dispensary License Transaction

MINNEAPOLIS, July 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that it has completed its previously announced acquisition of all of the issued and outstanding limited liability company membership interests of FarmX, LLC d/b/a PhytoNatural (“PhytoNatural”), jointly with Vive Penn, LLC (“Vive”), a joint venture […]

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier […]

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolio Portfolio now positioned to address the majority of U.S. iohexol injection market demand across key presentations Demonstrates Amneal’s continued leadership in complex injectables and hospital […]

Damora Announces Redomestication from Delaware to Cayman Islands

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) — Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding […]